Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology... Show more
LPCN is expected to report earnings to -31 cents per share on November 11
Q3'26
Est.
$-0.32
Q2'26
Beat
by $0.12
Q1'26
Missed
by $0.07
Q1'23
Missed
by $0.01
Q4'22
Missed
by $0.31
The last earnings report on August 04 showed earnings per share of -31 cents, beating the estimate of -43 cents. With 26.77K shares outstanding, the current market capitalization sits at 17.23M.